Beta-thalassemia

Genetics in Medicine

Volumn 12, Issue 2, 2010, Pages 61-76

  Cao, Antonio ^a,c   Galanello, Renzo ^b  

^a CNR   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Osp Regionale per le Microcitemie   (Italy)

Author keywords

Beta thalassemia; Iron chelation; Thalassemia intermedia; Thalassemia major; Thalassemia prevention

Indexed keywords

BETA GLOBIN; BILIRUBIN; BONE MORPHOGENETIC PROTEIN; DEFERASIROX; DEFERIPRONE; HEMOGLOBIN F; IRON; SMAD PROTEIN;

ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; BONE METABOLISM; CHROMOSOME 11; CHROMOSOME ARM; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; GENE DELETION; GENE MAPPING; GENE MUTATION; GENE SILENCING; GENETIC COUNSELING; GENETIC VARIABILITY; GLOBIN GENE; HETEROZYGOSITY; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MALARIA FALCIPARUM; MASS SCREENING; PHENOTYPE; PRENATAL DIAGNOSIS; PROTEIN EXPRESSION; PSEUDOGENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL GENE THERAPY; THALASSEMIA MAJOR;

BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; FEMALE; GENETIC TESTING; GLOBINS; HETEROZYGOTE DETECTION; HUMANS; MULTIGENE FAMILY; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 77149153067     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181cd68ed     Document Type: Review

References (153)

1. Wheatherall DJ, Clegg JB. The thalassemia syndromes. 4th ed. Oxford, England: Blackwell Science Ltd, 2001.
2. Weatherall DJ, Clegg JB, Higgs DR, Wood WG. The hemoglobinopathies. In: Scriver CR, Beaudet Al, Sly WS, Valle D, Vogelstein B, editors. The metabolic and molecular bases of inherited disease (OMMBID). Chapter 101. New York, NY: McGraw-Hill, 2002. Available at: www.ommbid.com. Accessed December 31, 2007.
3. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Baillieres Clin Haematol 1993;6:215-262.
4. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353: 1135-1146.
5. Cao A, Galanello R. Beta-thalassemia. Available at: http://www. geneclinics. org. Accessed December 1, 2005.
6. Olivieri N, Weatherall DJ. Clinical aspects of /3-thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of hemoglobin, genetics, pathophysiology, and clinical management. Cambridge, England: Cambridge University, 2001:277-341.
7. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, et al. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 2006;91: 1193-1202.
8. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-139.
9. Origa R, Fiumana E, Gamberini MR, et al. Osteoporosis in beta-thalassemia: clinical and genetic aspects. Ann N YAcadSci 2005;1054:451-456.
10. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004;124:114-117.
11. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
12. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36-43.
13. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783-788. (Pubitemid 36917762)
14. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
15. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005;2:399-409.
16. Tanno T, BhanuNV, OnealPA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-1101.
17. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92:583-588.
18. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007; 109:5027-5035.
19. Weizer-Stern O, Adamsky K, Amariglio N, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol 2006;135:129-138.
20. Viprakasit V, Gibbons RJ, Broughton BC, et al. Mutations in the general transcription factor TFIIH result in beta-thalassaemia in individuals with trichothiodystrophy. Hum Mol Genet 2001;10:2797-2802. (Pubitemid 34026461)
21. FresonK, Matthijs G, Thys C, et al. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet 2002;11:147-152.
22. Old J, Traeger-Synodinos J, Galanello R, Petrou M, Angastiniotis M. Prevention of Thalassemias and other hemoglobin disorders. Vol 2: Laboratory Methods. Nicosia, Cyprus: Thalassemia International Federation (TIF), 2005.
23. Vrettou C, Traeger-Synodinos J, Tzetis M, Malamis G, Kanavakis E. Rapid screening of multiple beta-globin gene mutations by real-time PCR on the LightCycler: application to carrier screening and prenatal diagnosis of thalassemia syndromes. Clin Chem 2003;49:769-776.
24. Ye BC, Zhang Z, Lei Z. Molecular analysis of alpha/beta-thalassemia in a southern Chinese population. Genet Test 2007;11:75-83.
25. Ho PJ, Hall GW, Luo LY, Weatherall DJ, Thein SL. Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? Br J Haematol 1998;100:70-78.
26. Galanello R, Dessi E, Melis MA, et al. Molecular analysis of beta zero-thalassemia intermedia in Sardinia. Blood 1989;74:823-827.
27. Cao A, Gasperini D, Podda A, Galanello R. Molecular pathology of thalassemia intermedia. Eur J Int Med 1990;1:227-236.
28. Rund D, Oron-Karni V, Filon D, Goldfarb A, Rachmilewitz E, Oppenheim A. Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am J Hematol 1997;54: 16-22.
29. Wainscoat JS, Thein SL, Weatherall DJ. Thalassaemia intermedia. Blood Rev 1987;1:273-279.
30. Gonzalez-Redondo JM, Stoming TA, Kutlar A, et al. A C-T substitution at nt-101 in a conserved DNA sequence of the promotor region of the beta-globin gene is associated with "silent" beta-thalassemia. Blood 1989; 73:1705-1711.
31. Bianco I, Cappabianca MP, Foglietta E, et al. Silent thalassemias: genotypes and phenotypes. Haematologica 1997;82:269-280.
32. Murru S, Pischedda MC, Cao A, et al. A promoter mutation of the beta-globin gene (-101 C->T) has an age-related expression pattern. Blood 1993;81:2818-2819.
33. Wainscoat JS, Kanavakis E, Wood WG, et al. Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia. Br J Haematol 1983;53:411-416.
34. Cao A, Galanello R, Rosatelli MC. Genotype-phenotype correlations in beta-thalassemias. Blood Rev 1994;8:1-12.
35. Pirastu M, Kan YW, Galanello R, Cao A. Multiple mutations produce delta beta° thalassemia in Sardinia. Science 1984;223:929-930.
36. Galanello R, Barella S, Satta S, Maccioni L, Pintor C, Cao A. Homozy-gosity for nondeletion delta-beta(0) thalassemia resulting in a silent clinical phenotype. Blood 2002;100:1913-1914.
37. Cao A, Melis MA, Galanello R, et al. Delta beta (F)-thalassaemia in Sardinia. J Med Genet 1982;19:184-192.
38. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009;145:455-467.
39. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 2008;105: 1620-1625.
40. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007;39:1197-1199.
41. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci USA 2007;104:11346-11351.
42. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008;105:11869-11874.
43. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839-1842.
44. Chen Z, Luo HY, Steinberg MH, Chui DH. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis 2009;42:144-149.
45. Thein SL, Weatherall DJ. A non-deletion hereditary persistence of fetal hemoglobin (HPFH) determinant not linked to the beta-globin gene complex. Prog Clin Biol Res 1989;316B:97-111.
46. Wahlberg K, Jiang J, Rooks H, et al. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 2009;114:1254-1262.
47. Sedgewick AE, Timofeev N, Sebastiani P, et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobi-nopathies. Blood Cells Mol Dis 2008;41:255-258.
48. Garner CP, Tatu T, Best S, Creary L, Thein SL. Evidence of genetic interaction between the beta-globin complex and chromosome 8q in the expression of fetal hemoglobin. Am J Hum Genet 2002;70:793-799.
49. Garner C, Silver N, Best S, et al. Quantitative trait locus on chromosome 8q influences the switch from fetal to adult hemoglobin. Blood 2004;104: 2184-2186.
50. Miyoshi K, Kaneto Y, Kawai H, et al. X-linked dominant control of F-cells in normal adult life: characterization of the Swiss type as hereditary persistence of fetal hemoglobin regulated dominantly by gene(s) on X chromosome. Blood 1988;72:1854-1860.
51. Dover GJ, Smith KD, Chang YC, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992;80:816-824.
52. Galanello R, Sanna S, Perseu L, et al. Amelioration of Sardinian beta-zero thalassemia by genetic modifiers. Blood 2009;114:3935-3937.
53. Galanello R, Ruggeri R, Paglietti E, Addis M, Melis MA, Cao A. A family with segregating triplicated alpha globin loci and beta thalassemia. Blood 1983;62:1035-1040.
54. Thein SL, Al-Hakim I, Hoffbrand AV. Thalassaemia intermedia: a new molecular basis. Br J Haematol 1984;56:333-337.
55. Kulozik AE, Thein SL, Wainscoat JS, et al. Thalassaemia intermedia: interaction of the triple alpha-globin gene arrangement and heterozygous beta-thalassaemia. Br J Haematol 1987;66:109-112.
56. Kanavakis E, Metaxotou-Mavromati A, Kattamis C, Wainscoat JS, Wood WG. The triplicated alpha gene locus and beta thalassaemia. Br J Haematol 1983;54:201-207.
57. Thompson CC, Ali MA, Vacovsky M, Boyadjian S. The interaction of anti 3.7 type quadruplicated alpha-globin genes and heterozygous beta-thalas-semia. Hemoglobin 1989;13:125-135.
58. Sollaino MC, Paglietti ME, Perseu L, Giagu N, Loi D, Galanello R. Association of alpha globin gene quadruplication and heterozygous beta thalassemia in patients with Thalassemia intermedia. Haematologica 2009; 94:1445-1448.
59. Harteveld CL, Refaldi C, Cassinerio E, Cappellini MD, Giordano PC. Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassemia intermedia phenotypes in beta-thalassemia heterozygous patients. Blood Cells Mol Dis 2008;40:312-316.
60. Thein SL. Dominant beta thalassaemia: molecular basis and pathophysiol-ogy. Br J Haematol 1992;80:273-277.
61. Murru S, Poddie D, Sciarratta GV, et al. A novel beta-globin structural mutant, Hb Brescia (beta 114 Leu-Pro), causing a severe beta-thalassemia intermedia phenotype. Hum Mutat 1992;1:124-128.
62. Thein SL. Is it dominantly inherited beta thalassaemia or just a beta-chain variant that is highly unstable? Br J Haematol 1999;107:12-21.
63. Badens C, Mattei MG, Imbert AM, et al. A novel mechanism for thalas-saemia intermedia. Lancet 2002;359:132-133.
64. Galanello R, Perseu L, Perra C, et al. Somatic deletion of the normal beta-globin gene leading to thalassaemia intermedia in heterozygous beta-thalassaemic patients. Br J Haematol 2004;127:604-606.
65. Huisman TH. Silent beta-thalassemia and thalassemia intermedia. Haematologica 1990;75(suppl 5):1-8.
66. Kong Y, Zhou S, Kihm AJ, et al. Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest 2004;114:1457-1466.
67. Lai MI, Jiang J, Silver N, et al. Alpha-haemoglobin stabilising protein is a quantitative trait gene that modifies the phenotype of beta-thalassaemia. Br J Haematol 2006;133:675-682.
68. Galanello R, Perseu L, Giagu N, Sole G, Perra C. AHSP expression in beta thalassemia carriers with thalassemia intermedia phenotype. Blood 2003; 102:Abstract 1881.
69. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001;2:245-255.
70. Galanello R, Piras S, Barella S, et al. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia. Br J Haematol 2001;115:926-928.
71. Dewey KW, Grossman H, Canale VC. Cholelithiasis in thalassemia major. Radiology 1970;96:385-388.
72. Borgna-Pignatti C, De Stefano P, Pajno D, Tomasi G, Gatti C. Cholelithiasis in children with thalassemia major: an ultrasonographic study. J Pe-diatr 1981;99:243-244.
73. Scutellari PN, Bighi S, Orzincolo C, Cervi PM, Nibbio A. Incidence of biliary calculosis in beta-thalassemic syndromes Minerva Pediatr 1981;33: 983-990.
74. Borgna-Pignatti C, Rigon F, Merlo L, et al. Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica 2003;88:1106-1109.
75. Galanello R, Perseu L, Melis MA, et al. Hyperbilirubinaemia in heterozygous beta-thalassaemia is related to co-inherited Gilbert's syndrome. Br J Haematol 1997;99:433-436.
76. Iolascon A, Faienza MF, Moretti A, Perrotta S, Miraglia del Giudice E. UGT1 promoter polymorphism accounts for increased neonatal appearance of hereditary spherocytosis. Blood 1998;91:1093.
77. Miraglia del Giudice E, Perrotta S, Nobili B, Specchia C, D'Urso G, Iolascon A. Coinheritance of Gilbert's syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis. Blood 1999;94:2259-2262.
78. Cappellini MD, Martinez di Montemuros F, Sampietro M, Tavazzi D, Fiorelli G. The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels. Br J Haematol 1999;104:928-929.
79. Galanello R, Cipollina MD, Carboni G, et al. Hyperbilirubinemia, glucose-6-phosphate-dehydrogenase deficiency and Gilbert's syndrome. Eur J Pe-diatr 1999;158:914-916. (Pubitemid 29482514)
80. Rees DC, Singh BM, Luo LY, Wickramasinghe S, Thein SL. Nontransfu-sional iron overload in thalassemia. Association with hereditary hemochro-matosis. Ann N Y Acad Sci 1998;850:490-494.
81. Longo F, Zecchina G, Sbaiz L, Fischer R, Piga A, Camaschella C. The influence of hemochromatosis mutations on iron overload of thalassemia major. Haematologica 1999;84:799-803.
82. Melis MA, Cau M, Deidda F, Barella S, Cao A, Galanello R. Mutation in HFE gene increases iron overload in beta-thalassemia carriers. Haematologica 2002; 87:242-245.
83. Piperno A, Mariani R, Arosio C, et al. Haemochromatosis in patients with beta-thalassaemia trait. Br J Haematol 2000;111:908-914.
84. Rees DC, Singh BM, Luo LY, Wickramasinghe S, Thein Sl. Genetic influenes on bone disease in thalassemia. Blood 1998;92:S532a.
85. Wonke B. Bone disease in beta-thalassaemia major. Br J Haematol 1998; 103:897-901.
86. Perrotta S, Cappellini MD, Bertoldo F, et al. Osteoporosis in beta-thalas-saemia major patients: analysis of the genetic background. Br J Haematol 2000;111:461-466.
87. Dresner Pollak R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta thalassemia major and intermedia. Br J Haematol 2000;111:902-907.
88. Wonke B, Jensen C, Hanslip JJ, et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11(suppl 3):795-801.
89. Weatherall DJ, Clegg JB, Kwiatkowski D. The role of genomics in studying genetic susceptibility to infectious disease. Genome Res 1997;7:967-973.
90. Hill AVS, Allsopp CEM, Kwiatkowski D. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.
91. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D. Variation in the TNF-alfa promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-511.
92. Fernandez-Reyes D, Craig AG, Kyes SA, et al. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol Genet 1997;6:1357-1360.
93. Melis MA, Pirastu M, Galanello R, Furbetta M, Tuveri T, Cao A. Pheno-typic effect of heterozygous alpha and beta 0-thalassemia interaction. Blood 1983;62:226-229.
94. Rosatelli C, Falchi AM, Scalas MT, Tuveri T, Furbetta M, Cao A. Hematological phenotype of the double heterozygous state for alpha and beta thalassemia. Hemoglobin 1984;8:25-35.
95. Tamagnini GP, Lopes MC, Castanheira ME, Wainscoat JS, Wood WG. Beta + thalassemia-Portuguese type: clinical, haematological and molecular studies of a newly defined form of beta thalassaemia. Br J Haematol 1983;54:189-200.
96. 2 beta-thalassemia. Blood 1988;72:530-533.
97. 2 (type 2) beta-thalassemia in Greece. Hematol Pathol 1994;8:25-34.
98. Ristaldi MS, Murru S, Loudianos G, et al. The C-T substitution in the distal CACCC box of the beta-globin gene promoter is a common cause of silent beta thalassaemia in the Italian population. Br J Haematol 1990;74:480-486.
99. Galanello R, Paglietti ME, Addis M, et al. Pitfalls in genetic counselling for beta-thalassemia: an individual with 4 different thalassemia mutations. Clin Genet 1988;33:151-155.
100. Cao A, Galanello R, Rosatelli MC. Prenatal diagnosis and screening of the haemoglobinopathies. Baillieres Clin Haematol 1998;11:215-238.
101. Galanello R, Barella S, Ideo A, et al. Genotype of subjects with borderline hemoglobin A2 levels: implication for beta-thalassemia carrier screening. Am J Hematol 1994;46:79-81.
102. Galanello R, Melis MA, Podda A, et al. Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome. Blood 1990;15:75:1747-1749.
103. Loudianos G, Cao A, Pirastu M, Vassilopoulos G, Kollia P, Loukopoulos D. Molecular basis of the delta thalassemia in cis to hemoglobin Knossos variant. Blood 1991;77:2087-2088.
104. Kattamis AC, Camaschella C, Sivera P, Surrey S, Fortina P. Human alpha-thalassemia syndromes: detection of molecular defects. Am J Hematol 1996;53:81-91.
105. Cao A, Rosatelli MC, Monni G, Galanello R. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002;29:305-328, vi-vii.
106. Mavrou A, Kouvidi E, Antsaklis A, Souka A, Kitsiou Tzeli S, Kolialexi A. Identification of nucleated red blood cells in maternal circulation: a second step in screening for fetal aneuploidies and pregnancy complications. Prenat Diagn 2007;27:150-153.
107. Cheung MC, Goldberg JD, Kan YW. Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood. Nat Genet 1996;14:264-268.
108. Dhallan R, Guo X, Emche S, et al. A non-invasive test for prenatal diagnosis based on fetal DNA present in maternal blood: a preliminary study. Lancet 2007;369:474-481.
109. Lo YM. Recent advances in fetal nucleic acids in maternal plasma. J His-tochem Cytochem 2005;53:293-296.
110. Eleftheriou A. Guidelines for the clinical management of thalassemia. Thalassemia International Federation. Available at: www.thalassaemia.org.cy. Accessed December 31, 2007.
111. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Hematol 2007;138:291-304.
112. Clark PR, Chua-Anusorn W, St Pierre TG. Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI [corrected]. Magn Reson Med 2003;49:572-575. Erratum in: Magn Reson Med 2003;49:1201.
113. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
114. Westwood MA, Firmin DN, Gildo M, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 2005;21:531-538.
115. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861. (Pubitemid 40070775)
116. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferriox-amine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355.
117. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003;121:938-948.
118. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587.
119. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100:1566-1569. Erratum in: Blood 2003;101:2460.
120. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferri-oxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-520.
121. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-496.
122. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalas-semia major. Blood 2006;107:3733-3737.
123. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of de-feriprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336.
124. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-3744.
125. Maggio A. Light and shadows in the iron chelation treatment of haemato-logical diseases. Br J Haematol 2007;138:407-421.
126. Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag 2007;3: 795-805.
127. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107:3436-3441.
128. Galanello R, Origa R. Once-daily oral deferasirox for the treatment of transfusional iron overload. Expert Rev Clin Pharmacol 2008;1:231-240.
129. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462.
130. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364.
131. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-1314.
132. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-1884.
133. Porcu M, Landis N, Salis S, et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. Eur J Heart Fail 2007;9:320-322.
134. Tanner MA, Galanello R, Dessì C, et al. Combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12.
135. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009;145:245-254.
136. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004;104:263-269.
137. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica 2008;93: 917-920.
138. Gaziev J, Lucarelli G. Stem cell transplantation for hemoglobinopathies. Curr Opin Pediatr 2003;15:24-31.
139. La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005;1054:186-195.
140. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003;101:2137-2143.
141. Walters MC, Quirolo L, Trachtenberg ET, et al. Sibling donor cord blood transplantation for thalassemia major: experience of the Sibling Donor Cord Blood Program. Ann N Y Acad Sci 2005;1054:206-213.
142. Orofino MG, Argiolu F, Sanna MA, et al. Fetal HLA typing in beta thalassaemia: implications for haemopoietic stem-cell transplantation. Lancet 2003;362:41-42.
143. Pace BS, Zein S. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction. Dev Dyn 2006;235:1727-1737.
144. Quek L, Thein SL. Molecular therapies in beta-thalassaemia. Br J Haema-tol 2007;136:353-365.
145. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood 2003;102:1529-1530.
146. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica 2004;89:1172-1178.
147. Sadelain M, Boulad F, Galanello R, et al. Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther 2007;18:1-9.
148. Rivella S, May C, Chadburn A, Rivière I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003;101:2932-2939.
149. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004;104:3445-3453.
150. Chang JC, Ye L, Kan YW. Correction of the sickle cell mutation in embryonic stem cells. Proc Natl Acad Sci USA 2006;103:1036-1040.
151. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
152. Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of bibroblasts into a pluripotent ES-cell-like state. Nature 2007;448:318-324.
153. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-1923.